Previous post Next post

Novartis revenues slowed in last quarter of 2025

Novartis revenues slowed to a standstill in the final quarter of 2025. The Swiss pharmaceutical firm presents a mixed outlook for the current year. +Get the most important news from Switzerland in your inbox Novartis sales grew just 1% year-on-year to $13.3 billion in the last three months of 2025. At constant exchange rates, this represents a 1% decrease. The pace of revenue growth has slowed considerably after double-digit growth in each of the first two quarters. For the full year 2025, Novartis generated sales of CHF54.5 billion (+8%). The company achieved the net growth in the high single-digit percentage range forecast by management. The bottom line was an annual profit of CHF14 billion after just under CHF12 billion in 2024. + Read how Trump upended the Swiss pharma industry Shareholders will receive an increased dividend of CHF 3.70 from CHF 3.50. In the current year, Novartis management is aiming for sales growth in the low single-digit percentage range at constant ... Full story here Are you the author?
About Swissinfo
Swissinfo
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.
Previous post See more for 3.) Swissinfo Business and Economy Next post
Tags: ,

Permanent link to this article: https://snbchf.com/2026/02/novartis-revenues-slowed-quarter-2025/

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This site uses Akismet to reduce spam. Learn how your comment data is processed.